Plasma biomarkers as predictors of recurrence of atrial fibrillation

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 6, 2015, Pages 424-433

  Lewicka, Ewa ^a   Dudzińska Gehrmann, Julita ^b   Dąbrowska Kugacka, Alicja ^a   Zagozdzon, Pawel ^a   Stepnowska, Emilia ^a   Lizewska, Aleksandra ^a   Kozłowski, Dariusz ^a   Raczak, Grzegorz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b MSW Hospital   (Poland)

Author keywords

Atrial fibrillation; Biomarkers; Recurrence of arrhythmia

Indexed keywords

ALDOSTERONE; AMIODARONE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; ENDOTHELIN 1;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; CARDIOVERSION; CONTROLLED STUDY; DUAL CHAMBER PACEMAKER; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTOR VARIABLE; RECURRENT DISEASE; SENSITIVITY AND SPECIFICITY; SINUS RHYTHM; VERY ELDERLY; BLOOD; PATHOLOGY; PROGNOSIS;

AGED; AGED, 80 AND OVER; ALDOSTERONE; ATRIAL FIBRILLATION; ATRIAL NATRIURETIC FACTOR; ELECTRIC COUNTERSHOCK; ENDOTHELIN-1; FEMALE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RECURRENCE; SENSITIVITY AND SPECIFICITY;

EID: 84936868580     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2882     Document Type: Article

References (40)

1. Zielonka A, Tkaczyszyn M, Mende M, et al. Atrial fibrillation in outpatients with stable coronary artery disease: Results from the multicenter RECENT study. Pol Arch Med Wewn. 2015; 125: 162-171.
2. Vaziri S, Larson M, Benjamin E, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation. 1994; 2: 724-730.
3. Schnabel R, Sullivan L, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): A community-based cohort study. Lancet. 2009; 9665: 739-745.
4. Niewada M, Członkowska A. Prevention of ischemic stroke in clinical practice: A role of internists and general practitioners. Pol Arch Med Wewn. 2014; 124: 540-548.
5. Ehrlich J, Hohnloser S, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006; 5: 512-518.
6. Goette A, Staack T, Röcken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000; 6: 1669-1677.
7. Wozakowska-Kapłon B. Changes in plasma natriuretic peptide levels in patients with atrial fibrillation after cardioversion. Int J Cardiol. 2010; 3: 436-437.
8. Bartkowiak R, Wozakowska-Kapłon B, Janiszewska G. Plasma NT-pro- ANP in patients with persistent atrial fibrillation who underwent successful cardioversion. Kardiol Pol. 2010; 1: 48-54.
9. Wozakowska-Kapłon B, Bartkowiak R, Grabowska U, Janiszewska G. B-type natriuretic peptide level after sinus rhythm restoration in patients with persistent atrial fibrillation - clinical significance. Kardiol Pol. 2010; 7: 781-786.
10. Wozakowska-Kapłon B, Bartkowiak R, Janiszewska G. A decrease in serum aldosterone level is associated with maintenance of sinus rhythm after successful cardioversion of atrial fibrillation. Pacing Clin Electrophysiol. 2010; 5: 561-565.
11. van Wamel AJ, Ruwhof C, van der Valk-Kokshoom L, et al. The role of angiotensin II, endothelin-1 and transforming growth factor-beta as autocrine/paracrine mediators of stretch-induced cardiomyocyte hypertrophy. Mol Cell Biochem. 2001; 218: 113-124.
12. Potter L, Yoder A, Flora D, et al. Natriuretic peptides: Their structures, receptors, physiologic functions and therapeutic applications. Handb Exp Pharmacol. 2009; 191: 341-366.
13. Rossi G, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin- 1 and the renin-angiotensin-aldosterone system. Cardiovasc Res. 1999; 2: 300-307.
14. De Bold A, Ma K, Zhang Y, et al. The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol. 2001; 8: 705-714.
15. Dabrowski R, Szwed H. Antiarrhythmic potential of aldosterone antagonists in atrial fibrillation. Cardiol J. 2012; 3: 223-229.
16. Möllmann H, Weber M, Elsässer A, et al. NT-ProBNP predicts rhythm stability after cardioversion of lone atrial fibrillation. Circ J. 2008; 6: 921-925.
17. Wozakowska-Kapłon B, Opolski G. Exercise-induced natriuretic peptide secretion predicts cardioversion outcome in patients with persistent atrial fibrillation: discordant ANP and B-type natriuretic peptide response to exercise testing. Pacing Clin Electrophysiol. 2010; 10: 1203-1209.
18. Lellouche N, Berthier R, Mekontso-Dessap A, et al. Usefulness of plasma B-type natriuretic peptide in predicting recurrence of atrial fibrillation one year after external cardioversion. Am J Cardiol. 2005; 11: 1380-1382.
19. Battaglia M, Pewsner D, Jüni P, et al. Accuracy of B-type natriuretic peptide tests to exclude congestive heart failure: Systematic review of test accuracy studies. Arch Intern Med. 2006; 10: 1073-1080.
20. Bakowski D, Wozakowska-Kapłon B, Opolski G. The influence of left ventricle diastolic function on natriuretic peptides levels in patients with atrial fibrillation. Pacing Clin Electrophysiol. 2009; 6: 745-752.
21. Arakawa M, Miwa H, Noda T, et al. Alternations in atrial natriuretic peptide release after DC cardioversion of non-valvular chronic atrial fibrillation. Eur Heart J. 1995; 7: 977-985.
22. Mabuchi N, Tsutamoto T, Maeda K, Kinoshita M. Plasma cardiac natriuretic peptides as biochemical markers of recurrence of atrial fibrillation in patients with mild congestive heart failure. Jpn Circ J. 2000; 10: 765-771.
23. Inoue S, Murakami Y, Sano K, et al. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail. 2000; 2: 92-96.
24. Ohta Y, Shimada T, Yoshitomi H, et al. Drop in plasma brain natriuretic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol. 2001; 4: 415-420.
25. Doyama K, Fukumoto M, Takemura G, et al. Expression and distribution of brain natriuretic peptide in human right atria. J Am Coll Cardiol. 1998; 7: 1832-1838.
26. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994; 1: 195-203.
27. Rossi A, Enriquez-Sarano M, Burnett J, et al. Natriuretic peptide levels in atrial fibrillation: A prospective hormonal and Doppler-echocardiographic study. J Am Coll Cardiol. 2000; 5: 1256-1262.
28. Arakawa M, Miwa H, Kambara K, et al. Changes in plasma concentrations of atrial natriuretic peptides after cardioversion of chronic atrial fibrillation. Am J Cardiol. 1992; 4: 550-552.
29. Fujiwara H, Ishikura F, Nagata S, et al. Plasma atrial natriuretic peptide response to direct current cardioversion of atrial fibrillation in patients with mitral stenosis. J Am Coll Cardiol. 1993; 2: 575-580.
30. Ari H, Binici S, Ari S, et al. The predictive value of plasma brain natriuretic peptide for the recurrence of atrial fibrillation six months after external cardioversion. Turk Kardiyol Dern Ars. 2008; 7: 456-460.
31. Van Den Berg M, Crijns H, Van Veldhuisen D, et al. Atrial natriuretic peptide in patients with heart failure and chronic atrial fibrillation: Role of duration of atrial fibrillation. Am Heart J. 1998; 2: 242-244.
32. Ono K, Tsujimoto G, Sakamoto A, et al. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature. 1994; 6487: 301-314.
33. Mackenzie L, Bootman M, Laine M, et al. The role of inositol 1, 4, 5-trisphosphate receptors in Ca(2+) signalling and the generation of arrhythmias in rat atrial myocytes. J Physiol. 2002; 541: 395-409.
34. Li X, Zima A, Sheikh F, et al. Endothelin-1-induced arrhythmogenic Ca2+ signaling is abolished in atrial myocytes of inositol-1, 4, 5- Trisphosphate(IP3)-receptor type 2-deficient mice. Circ Res. 2005; 12: 1274-1281.
35. Rossi G, Cavallin M, Nussdorfer G, Pessina A. The endothelin-aldosterone axis and cardiovascular diseases. J Cardiovasc Pharmacol. 2001; 38; Suppl 2: S49-S52.
36. Lüscher T, Barton M. Endothelins and endothelin receptor antagonists: Therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000; 19: 2434-2440.
37. Nakazawa Y, Ashihara T, Tsutamoto T, et al. Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart Rhythm. 2009; 6: 725-730.
38. Wozakowska-Kapłon B, Bartkowiak R, Janiszewska G, Grabowska U. Does atrial fibrillation affect plasma endothelin level? Cardiol J. 2010; 5: 471-476.
39. Goette A, Hoffmanns P, Enayati W, et al. Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol. 2001; 8: 906-909.
40. Pei D, Li L, Xu Z, et al. Expression of mineralocorticoid receptor and 11-beta-hydroxysteroid dehydrogenase type 2 in human atria during chronic atrial fibrillation: Study of 25 cases. Zhonghua Yi Xue Za Zhi. 2007; 87: 816-819.